Procter And Gamble Co's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Procter And Gamble Co (PG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Procter And Gamble Co vs Its Competitors
- TTM: Trailing 12-month revenue of 87,032M vs 723,922M combined for tracked competitors (10.7% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-2.6% annualized vs trailing 12 months), vs accelerating (+2.9%) for its tracked peer group.
- Growth: Procter And Gamble Co generated 1.5% revenue growth year over year in Q4 2026, vs 7.8% for its tracked competitors combined.
- Profitability: Its 14.5% net margin compares with 4.2% for the peer group.
- Scale: Procter And Gamble Co ranks #1 of 28 companies by market capitalization in the Personal & Household Products industry, holding 50.0% of industry market cap.
- Peer revenue share: Procter And Gamble Co accounted for 10.2% of combined revenue among its tracked peer group, down from 10.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.84M compares with $0.54M for the peer group (1.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PG Sales vs. its Competitors, Q4 2026
Procter And Gamble Co reported revenue growth of 1.50 % year on year in Q4 2026, below its competitors' combined revenue growth of 7.78 %.
With a net margin of 14.53 %, Procter And Gamble Co achieved higher profitability than its competitors (4.22 %).
Procter And Gamble Co generated 10.22 % of the combined sales of its peer group, down from 10.79 % a year earlier.
Procter And Gamble Co vs. its Competitors, Q4 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Procter And Gamble Co and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Procter and Gamble Co | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (11) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Procter And Gamble Co's competitor groups requires a Commercial License.
For context: the Personal & Household Products industry grew revenue -4.6% year over year, combined, vs 1.5% for Procter And Gamble Co. Procter And Gamble Co's share of combined industry revenue moved from 11.20% to 11.91%, a gain of 0.71 percentage points.
Procter And Gamble Co's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Procter and Gamble Co | Yes | Yes | Yes | No |
| Competitors combined (60) | ||||
| High-Confidence Competitors (13) | ||||
| Similar-Size Competitors (5) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PG Stock Performance relative to its Competitors
PG Stock Performance relative to High-Confidence Competitors
PG Stock Performance relative to Similar-Size Competitors
PG Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Horizon Kinetics Holding Corporation | 282.9% | Outperformed |
| 2 | Dupont De Nemours Inc | 282.9% | Outperformed |
| 3 | Merck and Co Inc | 282.9% | Outperformed |
| 4 | Sealed Air Corp | 282.9% | Outperformed |
| 5 | Eli Lilly And Company | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Procter And Gamble Co's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Procter And Gamble Co's Comment on Competition and Industry Peers
Publicly Traded Peers of Procter and Gamble Co
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Procter and Gamble Co | 361,061.51 | 87,032.00 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Coca Cola Co | 376,094.52 | 49,284.00 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Pepsico Inc | 175,916.50 | 96,904.00 |
| SUBTOTAL | 3,758,976.81 | 993,302.48 |
Sign in to see all competitors of Procter and Gamble Co.
Sources: Procter and Gamble Co's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Procter and Gamble Co versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Procter And Gamble Co's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Perrigo Company Plc | Named by the company | 85% |
| Amyris Inc | Named by the company | 85% |
| Grove Collaborative Holdings Inc | Named by the company | 85% |
| Olaplex Holdings Inc | Named by the company | 85% |
| Est e Lauder Companies Inc | Named by the company | 85% |
| The Honest Company Inc | Named by the company | 85% |
| Starco Brands Inc | Named by the company | 85% |
| Church and Dwight Co Inc | Named by the company | 85% |
| The Hain Celestial Group Inc | Named by the company | 85% |
| Prestige Consumer Healthcare Inc | Named by the company | 85% |
| Edgewell Personal Care Company | Named by the company | 85% |
| Nexgel Inc | Named by the company | 85% |
| Altamira Therapeutics Ltd | Named by the company | 85% |
| Helen Of Troy Limited | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Procter And Gamble Co's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Procter And Gamble Co's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Procter and Gamble Co | Fabric & Home Care 34.83 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Coca Cola Co | North America 40.11 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Pepsico Inc | PepsiCo Beverages North America 29.95 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Procter and Gamble Co.
Procter And Gamble Co's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Procter and Gamble Co | 361,062 | 836,846 | 155,231 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Coca Cola Co | 376,095 | 747,860 | 208,923 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Pepsico Inc | 175,917 | 316,680 | 34,363 |
| PEERS TOTAL | 3,397,915 | 538,451 | 59,010 |
Sign in to see all peers for Procter and Gamble Co.
Procter And Gamble Co's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Procter and Gamble Co | Non-US 52.05 % |
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Coca Cola Co | Non-US 60.63 % |
| Merck and Co Inc | EMEA 23.60 % |
| Pfizer Inc | United States 58.91 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Procter and Gamble Co.
Procter And Gamble Co's Position in Industry Market Structure
Market-capitalization share and concentration across all 26 companies in Procter And Gamble Co's industry classification, broader than the peer set above. Market cap in millions of $.Procter And Gamble Co ranks #1 of 26 companies by market capitalization in its industry, holding 49.97 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,920, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Procter and Gamble Co | 353,201 | 49.97 % |
| 2 | Haleon Plc | 85,034 | 12.03 % |
| 3 | Ecolab Inc | 78,895 | 11.16 % |
| 4 | Colgate palmolive Company | 68,626 | 9.71 % |
| 5 | Kenvue Inc | 1,234 | 5.2% |
| 6 | Est e Lauder Companies Inc | 1,234 | 5.2% |
| 7 | Church and Dwight Co Inc | 1,234 | 5.2% |
| 8 | The Clorox Company | 1,234 | 5.2% |
| 9 | E l f Beauty Inc | 1,234 | 5.2% |
| 10 | Yatsen Holding Limited | 1,234 | 5.2% |
Market cap and industry share for the rest of Procter And Gamble Co's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Procter And Gamble Co's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Procter and Gamble Co | 353,201 | -4.17 % |
| 2 | Haleon Plc | 85,034 | 5.05 % |
| 3 | Ecolab Inc | 1,234 | 12.3% |
| 4 | Colgate palmolive Company | 1,234 | 12.3% |
| 5 | Kenvue Inc | 1,234 | 12.3% |
| 6 | Est e Lauder Companies Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Procter And Gamble Co's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Procter And Gamble Co's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Personal & Household Products industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (41 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 50.18 % | 48.81 % (avg) | +1.4 pp |
| Operating Margin | 22.69 % | industry median | +15.5 pp |
| EBITDA Margin | 24.03 % | 5.40 % (avg) | +18.6 pp |
| Capital Intensity (Capex / Revenue) | - | 2.23 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Procter And Gamble Co's Valuation vs Competitive Position
Valuation multiples vs the Personal & Household Products industry average (41 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 22.3x | 29.0x | -6.8x |
| EV / EBITDA | 18.3x | 19.3x | -0.9x |
| P/B | 6.6x | 4.2x | +2.4x |
| Return on Equity | 30.05 % | industry aggregate | 5.47 % |
| Return on Invested Capital | 13.68 % | 12.14 % (avg) | 1.54 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Procter And Gamble Co's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 0.60 % | 6.05 % | 5.97 % | 10.36 % | -0.21 % | 4.55 % | 0.49 % | 1.08 % |
| Operating Margin | 19.67 % | 9.78 % | 23.04 % | 24.04 % | 21.61 % | 22.17 % | 23.57 % | 23.62 % |
| Return on Invested Capital | 8.88 % | 5.03 % | 12.63 % | 14.78 % | 13.57 % | 14.38 % | 13.95 % | 14.08 % |
| P/E | 59.8x | 73.0x | 27.1x | 25.0x | 25.7x | 24.9x | 26.9x | 21.7x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Procter And Gamble Co's Strategic Group Map
Every company in Procter And Gamble Co's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Procter And Gamble Co is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Procter And Gamble Co's BCG Growth-Share Matrix
Relative market share (vs Procter And Gamble Co's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Procter And Gamble Co falls in the Cash Cow quadrant: relative market share of 4.15x vs its largest competitor, in an industry growing revenue 1.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Procter And Gamble Co's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 2,920 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Procter And Gamble Co's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Procter And Gamble Co's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Procter And Gamble Co's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Procter And Gamble Co falls in the Medium attractiveness / High strength cell: Invest / Grow.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Procter And Gamble Co's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Market leader by capitalization in its industry (#1 of 26, 49.97 % share).
- Operating margin 15.5 points above the industry median.
- Return on equity 5.5 points above the industry aggregate.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-2.6% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- Trades at a lower P/E than the industry average (22.3x vs 29.0x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Procter And Gamble Co's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Procter and Gamble Co | 0.25 | 0.71 | 0.71 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Coca Cola Co | - | 1.31 | 1.33 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Pepsico Inc | 0.28 | 0.90 | 2.46 |
Sign in to see all peers for Procter and Gamble Co.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Procter And Gamble Co's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Procter and Gamble Co | Q2 2026 | +1.5 % | -15.0 % |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Coca Cola Co | Q1 2026 | +12.1 % | +18.9 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Pepsico Inc | Q2 2026 | +6.4 % | +134.9 % |
| PEERS TOTAL | +1.4 % | -6.5 % |
Sign in to see all peers for Procter and Gamble Co.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Procter And Gamble Co's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Procter and Gamble Co | Q2 2026 | +2.7 % | +2.7 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Coca Cola Co | Q1 2026 | +11.0 % | -13.9 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Pepsico Inc | Q2 2026 | +7.4 % | -9.4 % |
Sign in to see all peers for Procter and Gamble Co.
Procter And Gamble Co's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Procter and Gamble Co | 12.72% | 17.81% | 30.05% |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Coca Cola Co | 13.13% | 17.45% | 41.27% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Pepsico Inc | 9.63% | 13.23% | 50.13% |
Sign in to see all peers for Procter and Gamble Co.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Procter And Gamble Co's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Procter and Gamble Co | 22.62 | 4.15 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Johnson and Johnson | 31.48 | 6.78 |
| Coca Cola Co | 27.43 | 7.63 |
| Merck and Co Inc | 119.91 | 5.52 |
| Pepsico Inc | 16.84 | 1.82 |
| PEERS AVERAGE | 32.56 | 3.78 |
Sign in to see all peers for Procter and Gamble Co.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.